Eledon Pharmaceuticals Inc Stock Price, News & Analysis

Eledon Pharmaceuticals, a clinical-stage biopharmaceutical company, announced presentations for its lead product candidate, AT-1501, at the American Transplant Congress (ATC) from June 4-9, 2021. The presentations include Phase 1 data on AT-1501's safety, tolerability, and pharmacokinetics, alongside pre-clinical data demonstrating its effectiveness in preventing islet allograft rejection in nonhuman primates. Two additional posters will cover pharmacokinetics, toxicity, and characterization of AT-1501. More information is available on the ATC website.

Eledon Pharmaceuticals (NASDAQ: ELDN) plans to announce its financial results for Q1 2021 on May 13, 2021, after trading closes. The management will conduct a conference call and webcast at 4:30 PM ET to discuss these results. The company focuses on developing therapies for autoimmune diseases and ALS, with its lead compound AT-1501 targeting the CD40L pathway. This innovative approach aims to improve safety and efficacy in treatments. A recording of the event will be available on Eledon's website for one year.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced a new development strategy for AT-1501 in renal transplantation as requested by the FDA. The agency has asked for specific non-human primate data before starting a Phase 2 trial in the U.S. Consequently, Eledon will conduct evaluations in primate models, expected to be completed by late 2022. Despite this shift, other development programs continue as planned, and no safety concerns regarding AT-1501 have been reported. The CEO emphasized the potential of AT-1501 as a treatment option for renal transplant patients.

Eledon Pharmaceuticals has announced the appointments of David Hovland, Ph.D. as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer. Dr. Hovland brings over 20 years of R&D experience, previously serving at Urovant Sciences and Allergan, while Mr. Smith has a successful track record at Urovant and Allergan. Their expertise is expected to advance the development of AT-1501, a novel antibody targeting the CD40 ligand. The company will issue stock options as inducement grants for their roles.

Eledon Pharmaceuticals (NASDAQ: ELDN) reported its fourth quarter and full-year 2020 results, highlighting a net loss of $5.9 million for Q4 and $22.8 million for the year. The company has $114.2 million in cash as of December 31, 2020, allowing it to fund multiple Phase 2 trials of its lead asset, AT-1501. Key milestones include ongoing ALS trials and islet cell transplantation trials expected to start in Q2 2021. The acquisition of Anelixis Therapeutics in September 2020 has reshaped Eledon's focus on autoimmune diseases and transplantation.

Eledon Pharmaceuticals (NASDAQ: ELDN) will release its financial results for Q4 and the full year 2020 on March 30, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET. The company, focused on developing treatments for autoimmune diseases and ALS, is advancing its lead compound, AT-1501, a targeted anti-CD40L antibody. Eledon aims to provide enhanced therapeutic solutions in immunology and transplantation.

Eledon Pharmaceuticals has appointed Jeff Bornstein, M.D. as Chief Medical Officer effective April 5, 2021, and Paul Little as Chief Financial Officer immediately. These appointments aim to strengthen the leadership team as Eledon advances its Phase 2 trial of AT-1501 for ALS and plans for additional trials. Dr. Bornstein has extensive experience in biopharmaceuticals, previously working with major companies like Takeda and Biogen, while Mr. Little brings over 30 years of finance and operations expertise from roles in Sientra and Allergan. Both executives will receive inducement grants of stock options.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), a clinical stage biopharmaceutical company, announced that CEO David-Alexandre C. Gros, M.D. will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10. The presentation will be available on-demand starting March 9 at 7:00 am EST. Eledon focuses on developing targeted treatments for organ transplantation and immunological diseases, with its lead compound AT-1501, an anti-CD40L antibody aimed at improving immune regulation.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will present at the 10th annual SVB Leerink Global Healthcare Conference on February 24 at 4:20 p.m. EST. The live webcast can be accessed through Eledon's website, and a replay will be available for 90 days. Eledon focuses on developing targeted medicines for organ transplantation and immunological diseases, with its lead compound, AT-1501, targeting the CD40L pathway to potentially enhance treatment efficacy and safety.